,,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['mbc', 'breast', 'enhertu', 'destiny-breast04', '$azn']
#asco22 the most highly anticipated $azn/daiichi enhertu destiny-breast04 data are spectacular indeed! mpfs 9.9mo vs 5.1mo; hr=0.50; p&lt;0.001 mos 23.4mo vs 16.8mo; hr=0.64; p=0.001 redefining rx for ~60% of her2- mbc by creating a new category: her2-low 
#Biotech Investor | Recovering Scientist | May have L/S position in names mentioned | Opinions are strictly my own and not intended as investment advice